About Deep Genomics
Deep Genomics is a company based in Toronto (Canada) founded in 2015. Deep Genomics has raised $237.96 million across 4 funding rounds from investors including Fidelity Investments, ARE and Khosla Ventures. Deep Genomics offers products and services including AI Platform, BigRNA, and BigRNA+. Deep Genomics operates in a competitive market with competitors including Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
- Headquarter Toronto, Canada
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$237.96 M (USD)
in 4 rounds
-
Latest Funding Round
$180 M (USD), Series C
Jul 28, 2021
-
Investors
Fidelity Investments
& 12 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Deep Genomics
Deep Genomics offers a comprehensive portfolio of products and services, including AI Platform, BigRNA, and BigRNA+.
Uses AI to identify RNA targets and evaluate therapies for genetic conditions.
Foundation model for analyzing RNA biology and discovering new mechanisms.
Expanded model for pursuing complex genetic diseases and novel targets.
People of Deep Genomics
Unlock access to complete
Unlock access to complete
Funding Insights of Deep Genomics
Deep Genomics has successfully raised a total of $237.96M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $180 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series C — $180.0M
-
First Round
First Round
(18 Nov 2015)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Series C - Deep Genomics | Valuation | SoftBank Vision Fund | |
| Jan, 2020 | Amount | Series B - Deep Genomics | Valuation | Future Ventures | |
| Sep, 2017 | Amount | Series A - Deep Genomics | Valuation | Khosla Ventures |
Investors in Deep Genomics
Deep Genomics has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, ARE and Khosla Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in technology and startups.
|
Founded Year | Domain | Location | |
|
Venture capital investments are made in precision medicine companies.
|
Founded Year | Domain | Location | |
|
Early-stage startups are funded by this venture capital firm.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Deep Genomics
Financial Statements - Deep Genomics
Deep Genomics Comparisons
Competitors of Deep Genomics
Deep Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| domain | founded_year | HQ Location |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
Frequently Asked Questions about Deep Genomics
Deep Genomics was founded in 2015.
Deep Genomics is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Deep Genomics is a funded company, having raised a total of $237.96M across 4 funding rounds to date. The company's 1st funding round was a Series A of $12.96M, raised on Nov 18, 2015.
Deep Genomics has expertise in machine learning, genome biology and precision medicine. They are working on a new generation of computational technologies that can tell what will happen within a cell when DNA is altered by genetic variation, whether natural or therapeutic using machine learning and deep learning techniques. Their first product is SPIDEX, a comprehensive set of mutations and their predicted effects on RNA splicing across the entire human genome. They are making the SPIDEX database free for non-commercial purposes.
Deep Genomics's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
Deep Genomics offers AI Platform, BigRNA, and BigRNA+.
Deep Genomics has 13 investors. Key investors include Fidelity Investments, ARE, Khosla Ventures, CPP Investments, and Kensington Capital Partners.